Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit

Primary Care Diabetes

Volumn 12, Issue 1, 2018, Pages 45-50

  Thong, Ken Yan ^a   Yadagiri, Mahender ^b   Barnes, Dennis Joseph ^c   Morris, David Stuart ^d   Chowdhury, Tahseen Ahmad ^e   Chuah, Ling Ling ^f   Robinson, Anthony Michael ^g   Bain, Stephen Charles ^h   Adamson, Karen Ann ⁱ   Ryder, Robert Elford John ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CITY HOSPITAL   (United Kingdom)

^c Tunbridge Wells Hospital   (United Kingdom)

^d Northgate Health Centre   (United Kingdom)

^e ROYAL LONDON HOSPITAL   (United Kingdom)

^f CROYDON HEALTH SERVICES NHS TRUST   (United Kingdom)

^g ROYAL UNITED HOSPITAL   (United Kingdom)

^h ABERTAWE BRO MORGANNWG UNIVERSITY HEALTH BOARD   (United Kingdom)

ⁱ ST JOHN'S HOSPITAL   (United Kingdom)

Author keywords

Dapagliflozin; Genital fungal infection; Genital mycotic infection; SGLT2 inhibitor; Thrush

Indexed keywords

DAPAGLIFLOZIN; HEMOGLOBIN A1C; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGE; ARTICLE; BODY MASS; CLINICAL AUDIT; CLINICAL PRACTICE; DISEASE DURATION; DRUG WITHDRAWAL; ETHNICITY; FEMALE; GENITAL TRACT INFECTION; HUMAN; INFECTION RISK; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MYCOSIS; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE; URINARY TRACT INFECTION; URINE INCONTINENCE; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; GYNECOLOGIC DISEASE; MALE GENITAL SYSTEM DISEASE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; ODDS RATIO; RECURRENT DISEASE; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; BENZHYDRYL COMPOUNDS; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; MEDICAL AUDIT; MIDDLE AGED; MYCOSES; ODDS RATIO; RECURRENCE; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 85021379472     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2017.06.004     Document Type: Article

References (13)

1. DeFronzo, R.A., Davidson, J.A., Del Prato, S., The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 14 (2012), 5–14.
2. Heerspink, H.J., Perkins, B.A., Fitchett, D.H., Husain, M., Cherney, D.Z., Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
3. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373 (2015), 2117–2128.
4. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38 (2015), 140–149.
5. Ptaszynska, A., Johnsson, K.M., Parikh, S.J., De Bruin, T.W.A., Apanovitch, A.M., List, J.F., Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 37 (2014), 815–829.
6. Johnsson, K.M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S.J., List, J.F., Urinary tract infections in patients with diabetes treated with dapagliflozin. J. Diabetes Complicat. 27 (2013), 473–478.
7. Rosenstock, J., Ferrannini, E., Euglycemic diabetic ketoacidosis: a predictable, detectable and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38 (2015), 1638–1642.
8. Geerlings, S., Fonseca, V., Castro-Diaz, D., List, J., Parikh, S., Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res. Clin. Pract. 103 (2014), 373–381.
9. Johnsson, K.M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S.J., List, J.F., Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J. Diabetes Complicat. 27 (2013), 479–484.
10. Nyirjesy, P., Sobel, J.D., Fung, A., Mayer, C., Capuano, G., Ways, K., et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical outcomes. Curr. Med. Res. Opin. 30 (2014), 1109–1119.
11. Inagaki, N., Kondo, K., Yoshinari, T., Maruyama, N., Susuta, Y., Kuki, H., Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes. Metab. 15 (2013), 1136–1145.
12. Yale, J.F., Bakris, G., Cariou, B., Yue, D., David-Neto, E., Xi, L., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes. Metab. 15 (2013), 463–473.
13. Forxiga (dapagliflozin). Prescribing Information, 2012, Available at: http://www.guildlink.com.au/gc/ws/astra/pi.cfm?product=appforxi11016. (Revised October 2016).